Many of the pathogenic mutations identified in our dataset have been seen in other AML and MDS patient cohorts [29,30,31,32,33,34]; however, our study is the first to specifically characterize the distribution of TP53 mutations in patients with RCs. This evidence concerns the gene TP53 and myelodysplastic syndrome.